Advertisement

Topics

NEOVACS: NEOVACS ANNOUNCES LICENSE AGREEMENT FOR IFNalpha KINOID FOR TREATMENT OF LUPUS IN TURKEY

01:04 EDT 5 Jul 2017 | FinanzNachrichten

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES LICENSE AGREEMENT FOR IFNalpha KINOID FOR TREATMENT OF LUPUS IN TURKEY Agreement grants Centurion Pharma exclusive license to market...

Original Article: NEOVACS: NEOVACS ANNOUNCES LICENSE AGREEMENT FOR IFNalpha KINOID FOR TREATMENT OF LUPUS IN TURKEY

NEXT ARTICLE

More From BioPortfolio on "NEOVACS: NEOVACS ANNOUNCES LICENSE AGREEMENT FOR IFNalpha KINOID FOR TREATMENT OF LUPUS IN TURKEY"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Lupus
Lupus is a complex and poorly understood condition that affects many parts of the body and causes symptoms ranging from mild to life-threatening. There are several types of lupus. The main types are: discoid lupus erythematosus drug-induced lu...